These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 29115906)
1. Challenges of running a GMP facility for regenerative medicine in a public hospital. Viganò M; Giordano R; Lazzari L Regen Med; 2017 Oct; 12(7):803-813. PubMed ID: 29115906 [TBL] [Abstract][Full Text] [Related]
2. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products. Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916 [TBL] [Abstract][Full Text] [Related]
3. Role of the blood service in cellular therapy. Rebulla P; Giordano R Biologicals; 2012 May; 40(3):218-21. PubMed ID: 22063066 [TBL] [Abstract][Full Text] [Related]
4. Organ Chips: Quality Assurance Systems in Regenerative Medicine. Pasqualini FS; Emmert MY; Parker KK; Hoerstrup SP Clin Pharmacol Ther; 2017 Jan; 101(1):31-34. PubMed ID: 27709615 [TBL] [Abstract][Full Text] [Related]
5. Innovative regenerative medicines in the EU: a better future in evidence? Corbett MS; Webster A; Hawkins R; Woolacott N BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209 [TBL] [Abstract][Full Text] [Related]
6. Good Manufacturing Practice (GMP) Compliance for Phage Therapy Medicinal Products. Bretaudeau L; Tremblais K; Aubrit F; Meichenin M; Arnaud I Front Microbiol; 2020; 11():1161. PubMed ID: 32582101 [TBL] [Abstract][Full Text] [Related]
7. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764 [TBL] [Abstract][Full Text] [Related]
8. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607 [TBL] [Abstract][Full Text] [Related]
9. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation]. Mahalatchimy A; De Grove-Valdeyron N J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446 [TBL] [Abstract][Full Text] [Related]
10. [The Contribution of GMP-grade Hospital Preparation to Translational Research]. Yonezawa A; Kajiwara M; Minami I; Omura T; Nakagawa S; Matsubara K Yakugaku Zasshi; 2015; 135(8):943-7. PubMed ID: 26234351 [TBL] [Abstract][Full Text] [Related]
11. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products. Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433 [TBL] [Abstract][Full Text] [Related]
12. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020? Fang WH; Vangsness CT Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713 [TBL] [Abstract][Full Text] [Related]
13. Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK. Gardner J; Webster A; Barry J Regen Med; 2018 Jan; 13(1):29-39. PubMed ID: 29360014 [TBL] [Abstract][Full Text] [Related]
14. Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. Gaipa G; Introna M; Golay J; Nolli ML; Vallanti G; Parati E; Giordano R; Romagnoli L; Melazzini M; Biondi A; Biagi E Cytotherapy; 2016 Apr; 18(4):481-6. PubMed ID: 26971677 [TBL] [Abstract][Full Text] [Related]
15. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311 [TBL] [Abstract][Full Text] [Related]
16. Translating cell-based regenerative medicines from research to successful products: challenges and solutions. Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565 [TBL] [Abstract][Full Text] [Related]
17. An Industry-Driven Roadmap for Manufacturing in Regenerative Medicine. Hunsberger JG; Shupe T; Atala A Stem Cells Transl Med; 2018 Aug; 7(8):564-568. PubMed ID: 30009571 [TBL] [Abstract][Full Text] [Related]
18. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union. Kroes BH J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408 [TBL] [Abstract][Full Text] [Related]
19. Academic challenges on advanced therapy medicinal products' development: a regulatory perspective. Olesti E; Nuevo Y; Bachiller M; Guillen E; Bascuas J; Varea S; Saez-Peñataro J; Calvo G Cytotherapy; 2024 Mar; 26(3):221-230. PubMed ID: 38260921 [TBL] [Abstract][Full Text] [Related]
20. Update on Regulation of Regenerative Medicine in Taiwan. Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]